Veru is trading on Nasdaq and has net quarterly earnings. Appears to be able to call it's own shots so different ball game.Certainly not better science neccesarily. They seems to be using their drug to help with a lot of issues and generating reveue and net earnings. COVID is only one of their targets.

I often thought if we bump DM up to Non-Executive Chairman and bring in a new CEO with a PHD in Science that can articulate what we have then off we go but I think Eversana is playing that role hopefully now. Just a matter of DM getting out of the way. 

I think we need some success though with COVID or just spring into full blown BMO2 with proper financing.  The debenture has a grace period of 30 days I think so like the last time we will probably wait until the last minute which takes us to June 4th, I believe. I guess we will know one way or another. No more debentures giving up IP thanks very much. GLTA